Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.

We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.

To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.



COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Suspected or Confirmed
9186
COVID-19
Confirmed Cases
9153
Total counts of COVID-19 confirmed patients and count of COVID-19 suspected but not confirmed by testing.

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 905 1271 9186
          North America 480 699 5858
          Europe 240 311 1985
          Asia Pacific 36 45 134
          Latin America 80 141 618
          SWAAC 69 75 591
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Region

Patient Age


Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
7605
COVID-19
In-hospital Mortality
48%

Outcomes

Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as 'percentage (count)'
Total ARDS Cohort
Number cases 7605 5806
Age(years)
Median(IQR) 49(40,57) 50(41,57)
# observed 7605 5806
BMI, kg/m2
Median(IQR) 32(28,38) 32(28,38)
# observed 7093 5410
Sex
Male 71%(5405) 72%(4185)
Female 29%(2197) 28%(1619)
# observed 7602 5804
Race/Ethnicity
Black 12%(883) 11%(646)
White (Non-Hispanic) 39%(2983) 39%(2257)
Asian 10%(740) 9%(515)
Mid East, N African 4%(280) 4%(228)
Other 3%(241) 3%(190)
Unknown 4%(332) 5%(262)
Multiple 4%(335) 5%(283)
Hispanic 24%(1811) 25%(1425)
# observed 7605 5806
Pre-ECMO Comorbidities
No comorbidity 24%(1791) 23%(1318)
Cancer 2%(121) 2%(95)
Pregnancy 3%(200) 2%(142)
Immunocompromised 4%(275) 4%(212)
Diabetes 28%(2144) 30%(1719)
Pre-existing heart disease 4%(311) 3%(188)
Pre-existing lung disease 4%(302) 4%(237)
Pre-existing renal insuff. 3%(212) 3%(157)
Frailty 1%(52) 0%(28)
Asthma 11%(825) 11%(626)
BMI 51%(3886) 52%(3043)
Hypertension 35%(2684) 37%(2130)
# observed 7605 5806
Acute illness
ARDS 80%(6122) 100%(5806)
Acute heart failure 7%(512) 5%(275)
Myocarditis 2%(146) 1%(40)
Acute kidney injury 27%(2025) 28%(1621)
# observed 7605 5806
Pre-ECMO Cardiac Arrest
Yes 5%(394) 3%(176)
No 95%(7104) 97%(5542)
# observed 7498 5718
Pre-ECMO Co-Infection
No Co-infection 52%(3934) 49%(2825)
Bacterial pneumonia 42%(3159) 45%(2633)
Co-viral infection 10%(731) 9%(548)
Blood stream infection 16%(1202) 17%(1011)
Urinary tract infection 8%(597) 9%(501)
# observed 7602 5803

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as 'percentage (count)'
PreECLS PreECLS
Number cases 7605 5806
Noninvasive ventilation
Noninvasive ventilation prior to intubation 74%(5660) 77%(4451)
BiPAP 34%(2591) 35%(2046)
CPAP 13%(1024) 12%(696)
HFNC 49%(3716) 53%(3054)
# observed 7603 5804
Pre-ECLS intubation (days)
Median(IQR) 3.1(0.9,6.2) 3.4(1.0,6.3)
# observed 6603 5041
Ventilator mode
Conventional 97%(6584) 97%(5157)
# observed 6821 5307
PEEP, cm H2O
Median(IQR) 14.0(10.0,16.0) 14.0(10.0,16.0)
# observed 6127 4839
PIP, cm H2O
Median(IQR) 34.0(30.0,38.0) 34.0(30.0,38.0)
# observed 4969 3877
FiO2
Median(IQR) 1.00(0.95,1.00) 1.00(0.95,1.00)
# observed 6111 4756
PaO2/FiO2
Median(IQR) 71(58,92) 70(58,90)
# observed 5981 4654
PCO2
Median(IQR) 61(50,75) 61(51,76)
# observed 6266 4851
Pre-ECMO Support
Prone positioning 56%(4251) 59%(3392)
# observed 7543 5755
Neuromuscular blockers 71%(5345) 74%(4273)
# observed 7542 5753
Inhaled pulmonary vasodilators 29%(2220) 32%(1857)
# observed 7543 5755
Any vasoactive support 60%(4494) 59%(3378)
# observed 7541 5753
Norepinephrine 54%(4038) 54%(3087)
# observed 7541 5753
Therapies, Immunomodulators
Any therapy 88%(6670) 91%(5294)
Glucocorticoids 74%(5663) 78%(4505)
IVIG 2%(177) 2%(108)
Anti-cytokine 20%(1503) 22%(1257)
Lopinavir/Ritonavir 3%(221) 3%(187)
JAK inhibition 1%(41) 1%(35)
Chloroquine/hydroxychloroquine 12%(908) 13%(734)
Remdesivir 47%(3605) 51%(2951)
# observed 7605 5806
Support type
Respiratory 95%(7223) 100%(5790)
Cardiac 4%(296) 0%(7)
ECPR 1%(86) 0%(9)
# observed 7605 5806

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 23%(1784) 22%(1296)
Discharged alive to long-term acute care or unspecified location 13%(952) 14%(791)
Discharged to another hospital 12%(884) 11%(621)
Remain in the hospital (discharged from ICU) 0%(10) 0%(8)
Remain in the ICU 3%(213) 3%(155)
In-hospital death 49%(3762) 51%(2935)
Hours on ECMO 581 611
Tracheostomy 45%(3104) 48%(2528)
# observed 6882 5290
Select complications
Seizures 1%(56) 1%(45)
# observed 7413 5663
CNS infarction by US/CT/MRI 1%(99) 1%(63)
# observed 7413 5663
CNS hemorrhage by US/CT/MRI 7%(508) 7%(400)
# observed 7413 5663
Hemolysis 7%(500) 7%(408)
# observed 7413 5663
Oxygenator failure 11%(829) 12%(699)
# observed 7413 5663
Pump failure 1%(91) 1%(76)
# observed 7413 5663
Circuit change 15%(1081) 15%(848)
# observed 7413 5663
Thrombosis/Clots in circuit component 4%(280) 4%(222)
# observed 7413 5663
Discharge location
Home 29%(1060) 29%(796)
Transfer to LTAC or Rehab 7%(255) 8%(223)
Transfer to another hospital 24%(884) 23%(621)
Other/Unknown 4%(157) 4%(98)
*N/A - Data elements with n<5 are not displayed.

ELSO Ownership, No Rights to Publication, Disclaimer

The Dashboard content has been compiled and reported from a variety of sources, is not independently verified by ELSO, and is subject to change without notice. ELSO and its authorized agents and contractors make no representations or warranties about the quality, content, completeness, suitability, adequacy, sequence, accuracy, or timeliness of such content. ELSO disclaims any responsibility for any inaccuracy, whether by inclusion or omission, on the Dashboard or the Site, and disclaims any responsibility for subsequent change or withdrawal of data shown on the Dashboard or the Site, which is subject to alteration without notice. ELSO disclaims any and all warranties regarding this information and all liability whatsoever relating thereto. Any person who uses information obtained from this Dashboard does so at his or her own risk.

The Dashboard is provided as a public service to facilitate real-time sharing of information during the COVID-19 crisis for educational purposes only by health practitioners. ELSO owns the compilation of all data, and its use or publication by any third party is strictly forbidden. Publication or representation of this information as if it were statistically significant or part of a scientific study is irresponsible and misleading.

The tables are consistent with the Lancet Publication article but the data presented here is real time

Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, Bartlett RH, Tonna JE, Hyslop R, Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D, the Extracorporeal Life Support Organization. Extracorporeal Membrane Oxygenation Support in COVID-19: The Registry Report from the Extracorporeal Life Support Organization. Lancet. 2020; [In Press].

We’ve updated our Privacy Policy. By continuing to use this Service, you acknowledge you’ve read the updated Privacy Policy.